In only 2 days, the RapidSelection™ Test evaluates a broad range of FDA-approved drug options to assess their potential for treating your unique cancer.
We’ll deliver a test report 2 days after your sample collection. That’s the industry’s fastest turnaround time for cancer therapy guidance.
Step 1 - Request the Test Your Oncologist orders the RapidSelection™ Test for you. It takes only a few minutes.
Step 2 - Provide Sample Once collected, your sample reaches our lab within 24 hours to be immediately processed.
Step 3 - Review results After just 24 hours from sample processing, results are available to review online or via fax/paper.
In early studies, our innovative test matched the actual responses of 80% of treatments. Our predictive accuracy is being validated in multiple clinical trials.
Case Study AT025 Lung cancer patient gets a new therapy option Testing live cancer cells of a 77-year-old male with metastatic lung cancer reveals significant mass response to Carboplatin and Etoposide.
Case Study AT031 Testing confirms response failure to genomic biomarker-directed therapy Rapid Therapy Guidance test confirms the suspicion that metastatic non-small cell lung cancer with confirmed MET Exon 14 skipping mutation has stopped responding to Capmatinib.
Our lab tests a growing number of FDA-approved drugs on live tumor cells. You define a panel of up to 20 drugs per order to test.
Our drug catalog is growing, including over 100 FDA-approved drugs.
You define a panel of up to 20 drugs per order to test or leverage our drug selections.
Turnaround time: 2 days from sample collection. Sample types: Tissue, Malignant Fluids.
Each drug is scored between 0 and 100, and the list of drugs is sorted, with the highest scoring (likely effective) drugs at the top.
Simple and clear results you can leverage immediately for therapy decision-making.
The report includes graph and table of the mass change measurement data and the confidence (p-value) scores.
It explains how the scores are computed from the measurement data.
Your Expanded Cancer Treatment Plan
A cancer diagnosis can undermine your sense of control. The words, “We can try…” rarely restore it. The RapidSelection™ Test moves cancer treatment beyond trial and error with innovative, proprietary technology developed at MIT. We test live cancer cells outside the body against FDA-approved drugs and measure how they respond precisely. RapidSelection™ gives you the information you need to take control of your cancer care. In an unprecedented two-day turnaround time, you will know which drug options have the best potential to work for your unique cancer.
If you have further questions, please check the FAQs or contatact us.
How does RapidSelection™ predict drug effectiveness?
What drugs can RapidSelection™ measure?
How accurate is the RapidSelection™ Test?
How is the RapidSelection™ test different from other cancer therapy selection tests?
Is the RapidSelection™ test reimburseable?
Patient clinical outcomes show test predictive accuracy is over 80%
In early studies, our innovative test matched the actual responses of more than 80% of treatments. Our evidence is growing through multiple clinical research studies with major medical institutions throughout the United States.
Peer-reviewed Papers
JCO Precision Oncology* Next-generation ex vivo approaches, such as the RapidSelection™ technology, offer an alternative precision medicine approach for a broad population of patients with cancer.
Nature’s Communications Biology* The paper describes how our technology offers a promising complement to genomics-based cancer therapy guidance by testing drug efficacy directly on a patient’s tumor cells.
Leading Institutions
The institutions involved in our clinical studies include:
